Rare Blood Disorder Products | Scientific Exchange

Home > Novo Nordisk Inc. (NNI) Products > Rare Blood Disorder Products

Novo Nordisk Inc. (NNI) Products

Novo Nordisk has multiple products on the market for the treatment of Diabetes, Obesity, Growth Hormone Disorders, Hemophilia and Rare Bleeding Disorders. Access information and resources on each of our products below.

Rare Blood Disorders

Esperoct^®

antihemophilic factor (recombinant), glycopegylated-exei

Esperoct^® [antihemophilic factor (recombinant), glycopegylated-exei] is a coagulation Factor VIII concentrate indicated for use in adults and children with hemophilia A for on-demand treatment and control of bleeding episodes, perioperative management of bleeding, and routine prophylaxis to reduce the frequency of bleeding episodes.

Safety Data Sheet | Storage & Stability

Prescribing Information

Novoeight^®

antihemophilic factor (recombinant)

Novoeight^® (antihemophilic factor, recombinant) is indicated for use in adults and children with hemophilia A for on-demand treatment and control of bleeding episodes, perioperative management and routine prophylaxis to reduce the frequency of bleeding episodes.

Safety Data Sheet | Storage & Stability

Prescribing Information

NovoSeven^® RT

coagulation Factor VIIa (recombinant)

NovoSeven^® RT (coagulation Factor VIIa, recombinant) is indicated for treatment of bleeding episodes and perioperative management in adults and children with hemophilia A or B with inhibitors, congenital Factor VII (FVII) deficiency, Glanzmann’s thrombosthenia with refractoriness to platelets (with or without antibodies to platelets), and treatment of bleeding episodes and perioperative management in adults with acquired hemophilia.

Safety Data Sheet | Storage & Stability

Prescribing Information

Rebinyn^®

coagulation Factor IX (recombinant), glycoPEGylated

Rebinyn^® (Coagulation Factor IX (Recombinant), GlycoPEGylated), is a recombinant DNA-derived coagulation Factor IX concentrate indicated for use in adults and children with hemophilia B for on-demand treatment and control of bleeding episodes and perioperative management of bleeding.

Safety Data Sheet | Storage & Stability

Prescribing Information

Tretten^®

coagulation Factor XIII A-subunit (recombinant)

Tretten^®, Coagulation Factor XIII A-Subunit (Recombinant) is indicated for routine prophylaxis of bleeding in patients with congenital factor XIII A-subunit deficiency.

Safety Data Sheet | Storage & Stability

Prescribing Information

rare blood
disorders

Explore

Test Mediums

FlexPro^®

Test Medium

Safety Data Sheet

Additional Information

Speak to a live medical representative.

If you are a healthcare provider from the United States, click below to request information directly from the Novo Nordisk Medical Information department. If you are a patient, please visit https://www.novonordisk-us.com/contact-us.html or call 1-800-727-6500

Start Conversation

Search the Medical Information Database

The Scientific Exchange is a resource for U.S. Healthcare Professionals to learn more about disease states investigated by Novo Nordisk and our related products.

Begin Search

Scientific Exchange is a trademark of Novo Nordisk Health Care AG.
Novo Nordisk is a registered trademark of Novo Nordisk A/S.
Non-US Health Care Professionals, please go to www.novonordiskpro.com.